<DOC>
	<DOCNO>NCT00625469</DOCNO>
	<brief_summary>Pulmonary Arterial Hypertension ( PAH ) set Idiopathic Pulmonary Fibrosis ( IPF ) risk factor morbidity mortality peri-lung transplant ( LT ) set . Currently significant data support use pulmonary vasodilator PAH set interstitial lung disease IPF . The majority IPF patient PAH either rest exercise . The study hypothesis bosentan may improve morbidity mortality peri-LT setting IPF cohorts either rest exercise PAH .</brief_summary>
	<brief_title>Pulmonary Arterial Hypertension Secondary Idiopathic Pulmonary Fibrosis Treatment With Bosentan</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Idiopathic Pulmonary Fibrosis refer lung transplantation Minimum 50 meter 6 minute walk distance No significant underlie liver disease Significant liver disease cirrhosis non ambulatory previous adverse reaction/allergy Bosentan</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>idiopathic pulmonary fibrosis</keyword>
	<keyword>bosentan</keyword>
</DOC>